Avalo Therapeutics Inc (AVTX) Stock Price, Quote & News

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and i...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 522 8707

Website: www.avalotx.com

Address:

540 Gaither Road, Suite 400, Rockville, United States

DragonAlgo Apr. 24 at 4:45 PM

🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-05-15 | Strike: $12.50 | Type: PUT Option Plan (premium): Entry: $5.15 Stop: $3.71 TP1: $6.70 TP2: $8.76 TP3: $12.36 Rules-based execution profile. 🔗 https://dragonalgo.com

0 · Reply

Trapjaw Apr. 24 at 8:46 AM

$AVTX

0 · Reply

Trapjaw Apr. 24 at 8:35 AM

$AVTX result

1 · Reply

DragonAlgo Apr. 23 at 10:16 PM

🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $9.40 Stop: $6.77 TP1: $12.22 TP2: $15.98 TP3: $22.56 🔗 https://dragonalgo.com

0 · Reply

Trapjaw Apr. 23 at 8:09 PM

$AVTX

0 · Reply

Trapjaw Apr. 23 at 11:00 AM

$AVTX

0 · Reply

DragonAlgo Apr. 23 at 4:03 AM

🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $6.05 Stop: $4.36 TP1: $7.87 TP2: $10.29 TP3: $14.52 🔗 https://dragonalgo.com

0 · Reply

Trapjaw Apr. 22 at 10:16 AM

$AVTX

0 · Reply

DragonAlgo Apr. 22 at 9:22 AM

🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $6.90 Stop: $4.97 TP1: $8.97 TP2: $11.73 TP3: $16.56 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

Trapjaw Apr. 22 at 6:36 AM

$AVTX

0 · Reply

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Feb 24, 2026, 7:00 AM EST - 2 months ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Feb 18, 2026, 4:05 PM EST - 2 months ago

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Feb 2, 2026, 2:25 PM EST - 2 months ago

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Nov 6, 2025, 7:00 AM EST - 6 months ago

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Oct 29, 2025, 7:00 AM EDT - 6 months ago

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 1, 2025, 7:00 AM EDT - 7 months ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Sep 22, 2025, 7:00 AM EDT - 7 months ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Aug 7, 2025, 7:00 AM EDT - 9 months ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Jun 18, 2025, 7:00 AM EDT - 11 months ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 25, 2025, 3:20 PM EDT - 1 year ago

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Feb 4, 2025, 8:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 2, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jun 24, 2024, 4:01 PM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 17, 2024, 7:30 AM EDT - 2 years ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

May 13, 2024, 7:30 AM EDT - 2 years ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 1, 2024, 6:02 AM EDT - 2 years ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Mar 29, 2024, 4:01 PM EDT - 2 years ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Dec 27, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Nov 9, 2023, 7:00 AM EST - 2 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Avalo Completes Divestiture of AVTX-800 Series

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 2:10 AM EDT - 2 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jul 6, 2023, 4:01 PM EDT - 3 years ago

Avalo to Participate in SVB Securities Therapeutics Forum

Jun 26, 2023, 7:00 AM EDT - 3 years ago

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Jun 1, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at the Jefferies Healthcare Conference

May 22, 2023, 7:00 AM EDT - 3 years ago

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

May 15, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 10, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 4, 2023, 4:01 PM EDT - 3 years ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Mar 29, 2023, 7:30 AM EDT - 3 years ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Mar 7, 2023, 7:00 AM EST - 3 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Feb 2, 2023, 9:54 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Feb 2, 2023, 4:01 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

DragonAlgo Apr. 24 at 4:45 PM

0 · Reply

Trapjaw Apr. 24 at 8:46 AM

$AVTX

0 · Reply

Trapjaw Apr. 24 at 8:35 AM

$AVTX result

1 · Reply

DragonAlgo Apr. 23 at 10:16 PM

0 · Reply

Trapjaw Apr. 23 at 8:09 PM

$AVTX

0 · Reply

Trapjaw Apr. 23 at 11:00 AM

$AVTX

0 · Reply

DragonAlgo Apr. 23 at 4:03 AM

0 · Reply

Trapjaw Apr. 22 at 10:16 AM

$AVTX

0 · Reply

DragonAlgo Apr. 22 at 9:22 AM

0 · Reply

Trapjaw Apr. 22 at 6:36 AM

$AVTX

0 · Reply

DragonAlgo Apr. 21 at 3:19 PM

🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $7.05 Stop: $5.08 TP1: $9.17 TP2: $11.98 TP3: $16.92 🔗 https://dragonalgo.com

0 · Reply

Trapjaw Apr. 21 at 2:08 PM

$AVTX

0 · Reply

Trapjaw Apr. 21 at 8:27 AM

$AVTX https://lotustrial.com/

0 · Reply

Trapjaw Apr. 21 at 6:12 AM

$AVTX

0 · Reply

ubazuK Apr. 20 at 7:24 PM

$AVTX biotech spikes possible, high risk

1 · Reply

DragonAlgo Apr. 20 at 7:06 PM

🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $6.95 Stop: $5.00 TP1: $9.04 TP2: $11.81 TP3: $16.68 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Trapjaw Apr. 20 at 4:29 PM

$AVTX I hope they will give a date for the announcement of the results and not just present them out of the blue 🙀

1 · Reply

Trapjaw Apr. 20 at 10:58 AM

$AVTX

0 · Reply

DragonAlgo Apr. 19 at 12:05 AM

🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $7.65 Stop: $5.51 TP1: $9.95 TP2: $13.01 TP3: $18.36 🔗 https://dragonalgo.com

0 · Reply

QuantInsider Apr. 18 at 1:55 AM

What's going on with $AVTX? Despite the flat price action, a big player just dropped some serious cash on OTM put sweeps for mid-May We're talking 1,707 contracts and $332K in premium at strikes way below spot Saw this on InsiderFinance and it looks like fresh downside protection With around 490% IV, this could be early positioning for a dip Keep an eye out for more flow or price confirmation before jumping into bearish bets or unhedged longs

1 · Reply

negligiblecat Apr. 17 at 11:44 PM

$AVTX odds of beating placebo isnt that bad but odds of winning vs competition is far harder

0 · Reply

Trapjaw Apr. 17 at 3:28 PM

$AVTX

0 · Reply

Market Cap	394.03M
Revenue (ttm)	60,000.00
Net Income (ttm)	-78.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-130,433.34%
Debt to Equity Ratio	0.00

Volume	741,900
Avg Vol	742,594
Day's Range	N/A - N/A
Shares Out	26.71M
Stochastic %K	36%
Beta	0.93
Analysts	Strong Sell
Price Target	$40.09